Literature DB >> 26077506

A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.

Rena J Eudy1, Matthew M Riggs, Marc R Gastonguay.   

Abstract

A priori identifiability of mathematical models assures that for a given input/output experiment, the parameter set has one unique solution within a defined space, independent of the experimental design. Many biologic therapeutics exhibit target-mediated drug disposition (TMDD), and use of the full compartmental model describing this system is well documented. In practice, estimation of the full parameter set for TMDD models, given real-world clinical data, is characterized by convergence difficulties and unstable solutions. Still, the formal assessment of the a priori identifiability of these systems has yet to be reported. The exact arithmetic rank (EAR) approach was used to test the a priori identifiability of a TMDD model as well as model approximations. The full TMDD and quasi-equilibrium/rapid binding (QE/RB), quasi-steady state (QSS), and Michaelis-Menten (MM) approximations were fully identifiable, a priori, regardless of whether observations were taken from a single or multiple compartments. The results of these identifiability analyses indicated that the difficulty with TMDD model convergence, a posteriori, lies in the experimental design, not in the mathematical identifiability in the lack of samples from several compartments. Experiments can be tailored to resolve these structurally non-identifiable parameters, notwithstanding practical implementation challenges. This work highlights the importance of identifiability analyses, specifically how they can influence experimental design and selection of the appropriate model structure to describe a dynamic biological system.

Mesh:

Year:  2015        PMID: 26077506      PMCID: PMC4540726          DOI: 10.1208/s12248-015-9795-8

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  9 in total

1.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

2.  Target-mediated drug disposition model for drugs that bind to more than one target.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-29       Impact factor: 2.745

Review 3.  Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-07       Impact factor: 4.481

4.  Approximations of the target-mediated drug disposition model and identifiability of model parameters.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky; Tarundeep Kakkar; Peiming Ma
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-11-13       Impact factor: 2.745

5.  Comparison of approaches for parameter identifiability analysis of biological systems.

Authors:  Andreas Raue; Johan Karlsson; Maria Pia Saccomani; Mats Jirstrand; Jens Timmer
Journal:  Bioinformatics       Date:  2014-01-23       Impact factor: 6.937

6.  On linear models and parameter identifiability in experimental biological systems.

Authors:  Timothy O Lamberton; Nicholas D Condon; Jennifer L Stow; Nicholas A Hamilton
Journal:  J Theor Biol       Date:  2014-05-29       Impact factor: 2.691

7.  Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.

Authors:  Xiaoyu Yan; Donald E Mager; Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-10       Impact factor: 2.745

8.  Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.

Authors:  Lambertus A Peletier; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-01       Impact factor: 2.745

9.  Structural identifiability of systems biology models: a critical comparison of methods.

Authors:  Oana-Teodora Chis; Julio R Banga; Eva Balsa-Canto
Journal:  PLoS One       Date:  2011-11-22       Impact factor: 3.240

  9 in total
  3 in total

1.  MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.

Authors:  Silvia Maria Lavezzi; Enrica Mezzalana; Stefano Zamuner; Giuseppe De Nicolao; Peiming Ma; Monica Simeoni
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-11-10       Impact factor: 2.745

2.  Capacity limits of asialoglycoprotein receptor-mediated liver targeting.

Authors:  Charlotte Bon; Thomas Hofer; Alain Bousquet-Mélou; Mark R Davies; Ben-Fillippo Krippendorff
Journal:  MAbs       Date:  2017-09-06       Impact factor: 5.857

3.  Parameter Identifiability of Fundamental Pharmacodynamic Models.

Authors:  David L I Janzén; Linnéa Bergenholm; Mats Jirstrand; Joanna Parkinson; James Yates; Neil D Evans; Michael J Chappell
Journal:  Front Physiol       Date:  2016-12-05       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.